NCT06871410 2026-03-24
Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 1 Recruiting
Clinical Trials
9 trialsNCT05526924 2026-03-04
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
University of Chicago
Phase 1 Recruiting
NCT06005324 2025-06-08
Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer
University of Chicago
Phase 1 Recruiting
NCT01847326 2024-07-31
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer
University of Chicago
Phase 1 Completed
NCT03463733 2020-10-08
HUTMZ
Amsterdam UMC, location VUmc
Phase 1 Unknown
NCT00387933 2015-10-14
Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma
Duke University
Phase 1 Completed
NCT00613132 2013-02-20
Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG
Duke University
Phase 1 Completed
NCT00613054 2012-12-05
Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma
Duke University
Phase 1 Completed
NCT01521299 2012-08-28
A Dose Escalation Study of Hydroxyurea in Combination With SCH900776 in Advanced Malignant Solid Tumors
Dartmouth-Hitchcock Medical Center
Phase 1 Withdrawn